Searched for
LUPIN JAPAN SALES
Exploring ways to establish presence in China as part of APAC region push: LupinThe Mumbai-based firm expects to generate revenues of over USD 100 million from the region, excluding the Japanese market, over the next fe...- Lupin Q1 net profit dips 43% to Rs 203 croreDuring the quarter, the company's North America sales declined to Rs 1,185.8 crore.
- Lupin, Nichi-Iko tie up for commercialization of biosimilar Etanercept in JapanMumbai based Lupin pharma and Japan's Nichi-Iko have tied up for the distribution, promotion and sale of Lupin’s recently-filed biosimilar ...
- Lupin Q1 net profit jumps 55% to Rs 882 croreIts expenses were at Rs 3,334.08 crore, up 37.05 per cent, during the quarter as against Rs 2,432.58 crore of the last fiscal.
- Mumbai-based Lupin looks at buyouts in Japan after Sun Pharmaceutical’s entryWith the Japanese government pushing for generic prescription, Lupin is among the companies hunting for acquisitions in a country that is e...
- Lupin Q3 net profit rises 26% to Rs 601 croreNet sales of the company rose to Rs 3,144.91 crore for quarter under review as compared to Rs 2,982.97 crore in the same period of previous...
- Lupin forms Joint Venture with Japan's Yoshindo IncLupin's Etanercept biosimilar, developed by its Biotechnology Research Group in Pune will be the first product to be licensed for clinical ...
- Lupin launches generic GERD drug in the US marketUsed to treat gastroesophageal reflux disease.
- Lupin Q2 net profit up 40% at Rs 406 croreLupin had posted net profit of Rs 290.5 crore in July- September quarter of the previous fiscal, 2012-13.
- Lupin identifies cancer drugs as focus area in JapanLupin has identified cancer drugs as the new focus area in the Japanese market where patents on products worth $ 2 billion are expected to ...
- Lupin aims to double sales in Japan to $500 million in next 5 yearsDrug firm Lupin is targeting to double sales in Japan to $500 million (over Rs 2,600 crore) in the next five years on the back of enhanced ...
- Launch of anti-HIV drug Combivir generic a positive development for LupinThe launch of Combivir generic is a positive development for Lupin. However, it will have to share the mkt with competitors viz. Teva & Aur...
- Lupin mulls sale of its Indian unit that markets drugsLupin Limited, the world's largest maker of drugs to fight tuberculosis, is considering selling its unit that markets drugs in India, said ...
- Lupin aims to break into top 5 in Japanese marketDrug maker Lupin today said it is aiming to become one of the top five generic pharmaceutical companies in Japan in the next three years.
- Lupin scouts for buys in Latin AmericaThe company expects to launch 10 new products in Japan this year, considered the most difficult of three developed pharmaceutical markets -...
- Lupin settles litigation over Lunesta with Japanese firmDrug firm Lupin on Monday said it has settled ongoing litigation over Lunesta tablets, used in treating insomnia, with Japan-based Dainippo...
- Lupin buys 60% in S African generic coLupin has acquired 60% stake in Pharma Dynamics, a South African generic marketing firm.
- Lupin's Japanese arm gets nod to sell 10 productsThe company plans to launch these products by July 2008. Lupin is the first Indian co to get approval from the Japanese drug authorities to...
- Lupin to shift Japanese arm’s manufacturing to IndiaIn a bid to improve the profitability of its Japanese venture Kyowa Pharmaceutical Industry, Indian drug maker Lupin is planning to bring t...
- Lupin makes a leap into Japanese pharma marketLupin’s acquisition in Japan gives it a foothold in a large pharmaceutical market with relatively low generic penetration. Japan is the wor...
Load More
